Needham & Company Reiterates a ‘Strong Buy’ on NuVasive (NUVA)

By · May 11, 2010 · No comments
Financial · Tagged: , , ,

Needham & Company reiterates a 'Strong Buy' rating on NuVasive Inc. (Nasdaq: NUVA), price target $60.

Needham analyst says, "We expect significant upside to NUVA’s share price if NUVA continues to meet or beat numbers and demonstrates EPS leverage in 2010. Revenue growth far exceeds industry average and is sustainable for several years with continued market share gains. NUVA is expected to grow sales 33% in 2010, 28% in 2011, and 26% in 2012. Our medtech industry average is nearly half of NUVA’s growth rate, yet NUVA is trading at 2.4x forward rev estimate, compared to the medtech average of 3.0x."

To see all the upgrades/downgrades on shares of NUVA, visit our Analyst Ratings page.

NuVasive, Inc. (NuVasive) is a medical device company. It focuses on the designing, developing and marketing of products for the surgical treatment of spine disorders.

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.
←
→

© 2012 OrthoSpineNews